Leaderboards/Acute Myeloid Leukemia Research

Acute Myeloid Leukemia Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Álex Bataller
The University of Texas MD Anderson Cancer Center
2
Caitlyn Vlasschaert
Queen's University
3
Daniel Hormaechea‐Agulla
Baylor College of Medicine
4
Ze-Wei Huang
Sun Yat-sen University
5
Abhishek Niroula
Broad Institute
6
Joshua S. Weinstock
University of Michigan
7
Alexander Waclawiczek
German Cancer Research Center
8
Niels Asger Jakobsen
University of Oxford
9
Xiaoyan Hu
Virginia Commonwealth University
10
Zhong‐Shi Lyu
Peking University

Papers

1
Publication in Cell stem cell (2024) [98 citations, W4399970144]
Cell stem cell|2024
98 cit.
2
Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Nature Medicine|2024
75 cit.
3
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
The Lancet Haematology|2024
23 cit.
4
Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD
Journal of the American Society of Nephrology|2025
16 cit.
5
Gene regulatory network inference from CRISPR perturbations in primary CD4+ T cells elucidates the genomic basis of immune disease
Cell Genomics|2024
13 cit.
6
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Haematologica|2024
12 cit.
7
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
Blood Cancer Journal|2025
10 cit.
8
Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
Blood|2024
8 cit.
9
An arms‐race against resistance: leukemic stem cells and lineage plasticity
Molecular Oncology|2024
7 cit.
10
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
Blood Advances|2024
6 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Ndiya Ogba
National Comprehensive Cancer Network
2
Liran I. Shlush
Maccabi Healthcare Services
3
Jyoti Nangalia
Wellcome Sanger Institute
4
Lin Fu
National Clinical Research Center for Digestive Diseases
5
Constadina Arvanitis
Stanford University
6
Ing Soo Tiong
The University of Melbourne
7
Haobin Ye
Fudan University
8
Anna Krug
University of Colorado Anschutz Medical Campus
9
Lisa McGinnis
Stanford Medicine
10
David A. Sallman
Moffitt Cancer Center

Papers

1
Life histories of myeloproliferative neoplasms inferred from phylogenies.
RePEc: Research Papers in Economics|2022
231 cit.
2
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Journal of Clinical Oncology|2023
171 cit.
3
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Journal of Clinical Oncology|2023
121 cit.
4
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
The Lancet Haematology|2023
93 cit.
5
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
The Lancet Haematology|2023
89 cit.
6
Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis
Nature Genetics|2024
85 cit.
7
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)
Blood|2022
63 cit.
8
Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis
Nature Communications|2023
60 cit.
9
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
Journal of Clinical Oncology|2022
47 cit.
10
<i>TP53</i> Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates
American Society of Clinical Oncology Educational Book|2024
37 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
John E. Dick
University of Toronto
2
Ayalew Tefferi
Mayo Clinic
3
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
4
Benjamin L. Ebert
Dana-Farber Cancer Institute
5
Clara D. Bloomfield
North Shore University Hospital
6
Ross L. Levine
Memorial Sloan Kettering Cancer Center
7
Hartmut Döhner
University Hospital Ulm
8
Timothy J. Ley
Washington University in St. Louis
9
Jaroslaw P. Maciejewski
Cleveland Clinic
10
Daniel G. Tenen
Harvard University

Papers

1
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Nature Medicine|1997
6.9k cit.
2
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
New England Journal of Medicine|2014
4.7k cit.
3
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Nature|1994
4.7k cit.
4
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Nature|2006
4.1k cit.
5
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
New England Journal of Medicine|2000
3.3k cit.
6
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
Journal of Clinical Oncology|1999
3.3k cit.
7
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Blood|2022
3k cit.
8
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell|2005
3k cit.
9
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood|2022
2.7k cit.
10
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Journal of Clinical Oncology|2003
2.7k cit.

Reagents for Acute Myeloid Leukemia Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Thermo Fisher ScientificEvidence 69

CD34 Antibody (581), TRI-COLOR&reg; conjugate, Molecular Probes&trade;

Cited in 14 papers
#CD34-581-06
View Evidence →
Thermo Fisher ScientificEvidence 69

CD34 Monoclonal Antibody (581), Biotin

Cited in 14 papers
#CD34-581-15
View Evidence →
Thermo Fisher ScientificEvidence 69

CD34 Monoclonal Antibody (581), APC

Cited in 14 papers
#CD34-581-05
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

Phospho-Zap-70 (Tyr319)/Syk (Tyr352) (65E4) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 532 Conjugate)

Cited in 28 papers
#80986$486
View Evidence →
Cell Signaling TechnologyEvidence 64

PA28 alpha (D1C10) Rabbit Monoclonal Antibody

Cited in 19 papers
#9643$161,351
View Evidence →
Cell Signaling TechnologyEvidence 61

p56Dok-2 Antibody

Cited in 15 papers
#3914$317
View Evidence →